Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
NephroGenex Logo
NephroGenex Growth Score
28
CB Rank
3305346
Heat Score
1
NephroGenex is a drug-development company focusing on kidney disease and progression of diabetic kidney disease.
Founded
obfuscation
DelistedPost-IPO Equity Princeton, New Jersey, United States11-50 www.nephrogenex.com
Biotechnology
Diabetes
Health Care
Overview

NephroGenex
Total Funding
obfuscation
Growth Score
28
Heat Score
1

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score28
-4 pts
in past quarter
Heat Score 1
-13 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
See more interactive data and historical milestones on desktop for the best experience

About NephroGenex

CB Rank
3305346
NephroGenex is a drug-development company focusing on kidney disease and progression of diabetic kidney disease.
Founded
obfuscation
DelistedPost-IPO Equity Princeton, New Jersey, United States11-50 www.nephrogenex.com
Biotechnology
Diabetes
Health Care

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Venture - Series Unknown
OBF
in
obfuscation

Key People

Details

Legal Name NephroGenex Inc.
Operating Status Active
Stock Symbol  NASDAQ:NRX
Company Type For Profit
Founders  Wesley Fox
About the Company
NephroGenex is a drug-development company focusing on kidney disease. The Company is developing Pyridorin™ (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease.
Phone Number +1 609-986-1780
Predictions & Insights

Products & Services

PYRIDORIN® (pyridoxamine dihydrochloride)
An investigational drug candidate designed to slow the progression of diabetic nephropathy by inhibiting the formation of advanced glycation end products (AGEs).

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 4
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 4
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
East West Bank Logo
East West Bank
No
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
East West Bank Logo
East West Bank
No
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
East West Bank Logo
East West Bank
No
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
East West Bank Logo
East West Bank
No
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
East West Bank Logo
East West Bank
No
Post-IPO Equity - NephroGenex Logo
Post-IPO Equity - NephroGenex
—
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 1 Board Members and Advisors 1

Employee Profiles

Board Members and Advisors

News

News and Press

News•Sep 30, 2015
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 22, 2015
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 17, 2015
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 16, 2015
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

IT Spend

$32.6KThis year, NephroGenex is projected to spend $32.6K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Touch Monitor Logo
Touch Monitor
90
Touch Screen Monitor Logo
Touch Screen Monitor
90
AutoCAD Logo
AutoCAD
85

Actively Used Products

10NephroGenex uses 10 technology products and services including HTML5, Wordpress, and  Google Fonts, according to G2 Stack.

Active Website Tech Count

8NephroGenex is actively using 8 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, SSL by Default, and  CommonCrawl Top 50m.

Total IP

1NephroGenex has 1 registered patent in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is NephroGenex's headquarters? NephroGenex is located in Princeton, New Jersey, United States.Who invested in NephroGenex? NephroGenex has 4 investors including East West Bank and  Care Capital.When was the last funding round for NephroGenex? NephroGenex closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are NephroGenex's competitors? Alternatives and possible competitors to NephroGenex may include Diapin Therapeutics, Glycadia, and  AceLink Therapeutics.How much funding has NephroGenex raised to date? NephroGenex has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(8c8a01a 1)
|